These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 33676770

  • 1. PARD3-ALK: A novel ALK fusion gene identified in a patient with lung adenocarcinoma.
    Yang L, Zhao W, Zhu H, Li X, Zhao G.
    Lung Cancer; 2021 Apr; 154():219-220. PubMed ID: 33676770
    [No Abstract] [Full Text] [Related]

  • 2. MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC.
    Fang W, Gan J, Hong S, Lu F, Zhang L.
    J Thorac Oncol; 2019 Jul; 14(7):e148-e151. PubMed ID: 31235041
    [No Abstract] [Full Text] [Related]

  • 3. PLB1-ALK: A novel head-to-head fusion gene identified by next-generation sequencing in a lung adenocarcinoma patient.
    Wang B, Chen R, Wang C, Chen H, Zhong D.
    Lung Cancer; 2021 Mar; 153():176-178. PubMed ID: 33483162
    [No Abstract] [Full Text] [Related]

  • 4. Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.
    He Z, Wu X, Ma S, Zhang C, Zhang Z, Wang S, Yu S, Wang Q.
    Clin Lung Cancer; 2019 Sep; 20(5):e548-e551. PubMed ID: 31281052
    [No Abstract] [Full Text] [Related]

  • 5. SMPD3-ALK: A novel ALK fusion gene in lung adenocarcinoma.
    Liang Y, Wang Y, Wang W, Zhao J, Xu M, Zheng M.
    Clin Genet; 2021 Mar; 99(3):488-489. PubMed ID: 33556194
    [Abstract] [Full Text] [Related]

  • 6. SRBD1-ALK, a Novel ALK Fusion Gene Identified in an Adenocarcinoma Patient by Next-Generation Sequencing.
    Hou X, Xu H, Chen L.
    J Thorac Oncol; 2019 Apr; 14(4):e72-e73. PubMed ID: 30922581
    [No Abstract] [Full Text] [Related]

  • 7. TMED2-ALK, a Novel ALK Fusion Gene Identified in a Patient With Lung Adenocarcinoma.
    Mao W, Chen R, Zhang J, Zheng M.
    J Thorac Oncol; 2020 Mar; 15(3):e37-e39. PubMed ID: 32093858
    [No Abstract] [Full Text] [Related]

  • 8. Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion.
    Ren H, Hou X, Eiken PW, Zhang J, Pierson KE, Nair AA, Davila JI, Kovarikova H, Jang JS, Johnson SH, Molina JR, Marks RS, Yang P, Yi JE, Mansfield AS, Jen J.
    Clin Lung Cancer; 2019 Mar; 20(2):e142-e147. PubMed ID: 30581091
    [No Abstract] [Full Text] [Related]

  • 9. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T, Chen Z, Gu J, Wang Y, Zhang J, Min L.
    Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
    [Abstract] [Full Text] [Related]

  • 10. Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib.
    Luo J, Gu D, Lu H, Liu S, Kong J.
    J Thorac Oncol; 2019 Dec; 14(12):e266-e268. PubMed ID: 31757376
    [No Abstract] [Full Text] [Related]

  • 11. A novel 5'ALK fusion identified by next generation sequencing and validated by IHC in a patient with lung adenocarcinoma.
    He Z, Zhu X, Zeng Q, Yu Z.
    Lung Cancer; 2021 Aug; 158():164-165. PubMed ID: 34120772
    [No Abstract] [Full Text] [Related]

  • 12. DNA and RNA sequencing revealed a complex intergenic-ALK fusion in a lung adenocarcinoma patient who responded to TKI therapy.
    Zhang J, Huang J, Li Q, Lin H, Luo Z, Chen R.
    Lung Cancer; 2021 Sep; 159():171-174. PubMed ID: 34266695
    [No Abstract] [Full Text] [Related]

  • 13. Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib.
    Wang YL, Wu ZZ, Zhang HR, Chen DS, Zhao X.
    Lung Cancer; 2021 Apr; 154():216-218. PubMed ID: 33637344
    [No Abstract] [Full Text] [Related]

  • 14. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
    Cao H, Zheng J, Zhao J, Guo XJ, Zhou JY, Ding W, Zhou JY.
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb 12; 43(2):120-125. PubMed ID: 32062881
    [Abstract] [Full Text] [Related]

  • 15. Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions.
    Fan J, Dai X, Wang Z, Huang B, Shi H, Luo D, Zhang J, Cai W, Nie X, Hirsch FR.
    Clin Lung Cancer; 2019 Jul 12; 20(4):e517-e530. PubMed ID: 31138506
    [Abstract] [Full Text] [Related]

  • 16. Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.
    Wu X, Wang W, Zou B, Li Y, Yang X, Liu N, Ma Q, Zhang X, Wang Y, Li D.
    Thorac Cancer; 2020 Jun 12; 11(6):1695-1698. PubMed ID: 32212216
    [Abstract] [Full Text] [Related]

  • 17. A Novel Intergenic Region between CENPA and DPYSL5-ALK Exon 20 Fusion Variant Responding to Crizotinib Treatment in a Patient with Lung Adenocarcinoma.
    Fei X, Zhu L, Zhou H, Qi C, Wang C.
    J Thorac Oncol; 2019 Sep 12; 14(9):e191-e193. PubMed ID: 31445731
    [No Abstract] [Full Text] [Related]

  • 18. A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib.
    Li M, Tang Q, Chen S, Wang Y.
    Lung Cancer; 2021 Jan 12; 151():98-100. PubMed ID: 33280926
    [No Abstract] [Full Text] [Related]

  • 19. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
    Hu S, Li Q, Peng W, Feng C, Zhang S, Li C.
    J Thorac Oncol; 2018 May 12; 13(5):e72-e74. PubMed ID: 29703539
    [No Abstract] [Full Text] [Related]

  • 20. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
    Chen HF, Wang WX, Xu CW, Huang LC, Li XF, Lan G, Zhai ZQ, Zhu YC, Du KQ, Lei L, Fang MY.
    Lung Cancer; 2020 Apr 12; 142():59-62. PubMed ID: 32114282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.